Posted On: 03/05/2015 4:33:16 PM
Post# of 30070
JN seems to have made a very bold statement: AMBS "highly attractive to investors".....appears he is getting excited about AMBS!
"Amarantus is now a commercial-stage company with LymPro and a clinical-stage company with eltoprazine and ESS. It’s also an Orphan-focused company with MANF. We believe Amarantus shares, although high risk, are highly attractive for investors today based on the potential success of its pipeline, and drugs like eltoprazine for the treatment of PD-LID."
"Amarantus is now a commercial-stage company with LymPro and a clinical-stage company with eltoprazine and ESS. It’s also an Orphan-focused company with MANF. We believe Amarantus shares, although high risk, are highly attractive for investors today based on the potential success of its pipeline, and drugs like eltoprazine for the treatment of PD-LID."
(0)
(0)
